;PMID: 8614402
;source_file_863.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..39] = [t:0..39]
;1)sentence:[e:45..201] = [t:45..201]
;2)section:[e:205..224] = [t:205..224]
;3)section:[e:228..311] = [t:228..311]
;4)sentence:[e:315..497] = [t:315..497]
;5)sentence:[e:498..588] = [t:498..588]
;6)sentence:[e:589..765] = [t:589..765]
;7)sentence:[e:766..936] = [t:766..936]
;8)sentence:[e:937..1087] = [t:937..1087]
;9)sentence:[e:1088..1259] = [t:1088..1259]
;10)sentence:[e:1260..1387] = [t:1260..1387]
;11)sentence:[e:1388..1797] = [t:1388..1797]
;12)sentence:[e:1798..1993] = [t:1798..1993]
;13)sentence:[e:1994..2179] = [t:1994..2179]
;14)section:[e:2180..2462] = [t:2180..2462]
;15)section:[e:2466..2510] = [t:2466..2510]

;section 0 Span:0..39
;Mol Endocrinol. 1995 Dec;9(12):1655-65.
(SEC
  (FRAG (NNP:[0..3] Mol) (NNP:[4..14] Endocrinol) (.:[14..15] .)
        (CD:[16..20] 1995) (IN:[21..27] Dec;9-LRB-) (CD:[27..29] 12)
        (HYPH:[29..30] -RRB-) (CD:[30..35] :1655) (NN:[35..36] -)
        (CD:[36..38] 65) (.:[38..39] .)))

;sentence 1 Span:45..201
;Hybridization of the complementary mRNAs for P450c21 (steroid 21-hydroxylase)
; and tenascin-X is prevented by sequence-specific binding of nuclear
;proteins.
;[80..85]:substance:"mRNAs"
;[90..97]:cyp450:"P450c21"
;[99..121]:cyp450:"steroid 21-hydroxylase"
;[128..138]:substance:"tenascin-X"
;[192..200]:substance:"proteins"
(SENT
  (S-HLN
    (NP-SBJ-1
      (NP (NN:[45..58] Hybridization))
      (PP (IN:[59..61] of)
        (NP (DT:[62..65] the) (JJ:[66..79] complementary) (NNS:[80..85] mRNAs)))
      (PP (IN:[86..89] for)
        (NP
          (NP
            (NP (NN:[90..97] P450c21))
            (NP (-LRB-:[98..99] -LRB-)
               (NN:[99..106] steroid) (NN:[107..121] 21-hydroxylase)
              (-RRB-:[121..122] -RRB-)))
          (CC:[124..127] and)
          (NP (NN:[128..138] tenascin-X)))))
    (VP (VBZ:[139..141] is)
      (VP (VBN:[142..151] prevented)
        (NP-1 (-NONE-:[151..151] *))
        (PP (IN:[152..154] by)
          (NP-LGS
            (NP
              (ADJP (NN:[155..163] sequence) (HYPH:[163..164] -)
                    (JJ:[164..172] specific))
              (NN:[173..180] binding))
            (PP (IN:[181..183] of)
              (NP (JJ:[184..191] nuclear) (NNS:[192..200] proteins)))))))
    (.:[200..201] .)))

;section 2 Span:205..224
;Speek M, Miller WL.
(SEC
  (FRAG (NNP:[205..210] Speek) (NNP:[211..213] M,) (NNP:[214..220] Miller)
        (NNP:[221..224] WL.)))

;section 3 Span:228..311
;Department of Pediatrics, University of California, San Francisco 94143-0978,
; USA.
(SEC
  (FRAG (NNP:[228..238] Department) (IN:[239..241] of)
        (NNP:[242..252] Pediatrics) (,:[252..253] ,) (NNP:[254..264] University)
        (IN:[265..267] of) (NNP:[268..278] California) (,:[278..279] ,)
        (NNP:[280..283] San) (NNP:[284..293] Francisco) (IN:[294..299] 94143)
        (NNP:[299..304] -0978) (,:[304..305] ,) (NNP:[307..310] USA)
        (.:[310..311] .)))

;sentence 4 Span:315..497
;The CYP21 gene that encodes the steroid 21-hydroxylase, P450c21, is
;overlapped  on the opposite strand of DNA by the TX-X gene encoding the
;extracellular matrix  protein, tenascin-X.
;[319..324]:cyp450:"CYP21"
;[347..369]:cyp450:"steroid 21-hydroxylase"
;[371..378]:cyp450:"P450c21"
;[421..424]:substance:"DNA"
;[432..436]:substance:"TX-X"
;[477..484]:substance:"protein"
;[486..496]:substance:"tenascin-X"
(SENT
  (S
    (NP-SBJ-2
      (NP
        (NP (DT:[315..318] The) (NN:[319..324] CYP21) (NN:[325..329] gene))
        (SBAR
          (WHNP-1 (WDT:[330..334] that))
          (S
            (NP-SBJ-1 (-NONE-:[334..334] *T*))
            (VP (VBZ:[335..342] encodes)
              (NP
                (NP (DT:[343..346] the) (NN:[347..354] steroid))
                (NP (NN:[355..369] 21-hydroxylase)))))))
      (,:[369..370] ,)
      (NP (NN:[371..378] P450c21)))
    (,:[378..379] ,)
    (VP (VBZ:[380..382] is)
      (VP (VBN:[383..393] overlapped)
        (NP-2 (-NONE-:[393..393] *))
        (PP-LOC (IN:[395..397] on)
          (NP
            (NP (DT:[398..401] the) (JJ:[402..410] opposite)
                (NN:[411..417] strand))
            (PP (IN:[418..420] of)
              (NP (NN:[421..424] DNA)))))
        (PP (IN:[425..427] by)
          (NP-LGS
            (NP (DT:[428..431] the) (NN:[432..436] TX-X) (NN:[437..441] gene))
            (VP (VBG:[442..450] encoding)
              (NP
                (NP (DT:[451..454] the) (JJ:[455..468] extracellular)
                    (NN:[469..475] matrix) (NN:[477..484] protein))
                (,:[484..485] ,)
                (NP (NN:[486..496] tenascin-X))))))))
    (.:[496..497] .)))

;sentence 5 Span:498..588
;These transcripts contain perfectly complementary segments  of 299 bases at
;their 3'-ends.
;[504..515]:substance:"transcripts"
(SENT
  (S
    (NP-SBJ (DT:[498..503] These) (NNS:[504..515] transcripts))
    (VP (VBP:[516..523] contain)
      (NP
        (NP
          (ADJP (RB:[524..533] perfectly) (JJ:[534..547] complementary))
          (NNS:[548..556] segments))
        (PP (IN:[558..560] of)
          (NP (CD:[561..564] 299) (NNS:[565..570] bases))))
      (PP (IN:[571..573] at)
        (NP (PRP$:[574..579] their)
          (NML (CD:[580..581] 3) (SYM:[581..582] '))
          (HYPH:[582..583] -) (NNS:[583..587] ends))))
    (.:[587..588] .)))

;sentence 6 Span:589..765
;As these genes are tandemly duplicated and are  transcribed in the adrenal
;cortex, we investigated whether these  self-complementary transcripts formed
;RNA-RNA hybrids in vivo.
;[741..756]:substance:"RNA-RNA hybrids"
(SENT
  (S
    (SBAR-ADV (IN:[589..591] As)
      (S
        (NP-SBJ-1 (DT:[592..597] these) (NNS:[598..603] genes))
        (VP
          (VP (VBP:[604..607] are)
            (ADVP (RB:[608..616] tandemly))
            (VP (VBN:[617..627] duplicated)
              (NP-1 (-NONE-:[627..627] *))))
          (CC:[628..631] and)
          (VP (VBP:[632..635] are)
            (VP (VBN:[637..648] transcribed)
              (NP-1 (-NONE-:[648..648] *))
              (PP (IN:[649..651] in)
                (NP (DT:[652..655] the) (JJ:[656..663] adrenal)
                    (NN:[664..670] cortex))))))))
    (,:[670..671] ,)
    (NP-SBJ (PRP:[672..674] we))
    (VP (VBD:[675..687] investigated)
      (SBAR (IN:[688..695] whether)
        (S
          (NP-SBJ (DT:[696..701] these)
            (ADJP (AFX:[703..707] self) (HYPH:[707..708] -)
                  (JJ:[708..721] complementary))
            (NNS:[722..733] transcripts))
          (VP (VBD:[734..740] formed)
            (NP
              (NML (NN:[741..744] RNA) (HYPH:[744..745] -) (NN:[745..748] RNA))
              (NNS:[749..756] hybrids))
            (ADVP (FW:[757..759] in) (FW:[760..764] vivo))))))
    (.:[764..765] .)))

;sentence 7 Span:766..936
;Formation of  heterogeneous nuclear ribonucleoprotein complexes between
;nascent RNA  transcripts and nuclear proteins might modulate such potential
;RNA-RNA  interactions.
;[802..829]:substance:"ribonucleoprotein complexes"
;[846..862]:substance:"RNA  transcripts"
;[875..883]:substance:"proteins"
;[914..917]:substance:"RNA"
;[918..921]:substance:"RNA"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[766..775] Formation))
      (PP (IN:[776..778] of)
        (NP (JJ:[780..793] heterogeneous) (JJ:[794..801] nuclear)
           (NN:[802..819] ribonucleoprotein) (NNS:[820..829] complexes)))
      (PP (IN:[830..837] between)
        (NP
          (NP (JJ:[838..845] nascent)
             (NN:[846..849] RNA) (NNS:[851..862] transcripts))
          (CC:[863..866] and)
          (NP (JJ:[867..874] nuclear) (NNS:[875..883] proteins)))))
    (VP (MD:[884..889] might)
      (VP (VB:[890..898] modulate)
        (NP (JJ:[899..903] such) (JJ:[904..913] potential)
          (NML (NN:[914..917] RNA) (HYPH:[917..918] -) (NN:[918..921] RNA))
          (NNS:[923..935] interactions))))
    (.:[935..936] .)))

;sentence 8 Span:937..1087
;Using a double RNase protection assay, we found that these RNAs  form very
;small amounts of double-stranded RNA-RNA hybrids in adrenal cells in  vivo.
;[952..957]:substance:"RNase"
;[996..1000]:substance:"RNAs"
;[1045..1060]:substance:"RNA-RNA hybrids"
(SENT
  (S
    (S-MNR
      (NP-SBJ (-NONE-:[937..937] *))
      (VP (VBG:[937..942] Using)
        (NP (DT:[943..944] a) (JJ:[945..951] double) (NN:[952..957] RNase)
            (NN:[958..968] protection) (NN:[969..974] assay))))
    (,:[974..975] ,)
    (NP-SBJ (PRP:[976..978] we))
    (VP (VBD:[979..984] found)
      (SBAR (IN:[985..989] that)
        (S
          (NP-SBJ (DT:[990..995] these) (NNS:[996..1000] RNAs))
          (VP (VBP:[1002..1006] form)
            (NP
              (NP
                (ADJP (RB:[1007..1011] very) (JJ:[1012..1017] small))
                (NNS:[1018..1025] amounts))
              (PP (IN:[1026..1028] of)
                (NP
                  (ADJP (JJ:[1029..1035] double) (HYPH:[1035..1036] -)
                        (JJ:[1036..1044] stranded))
                  
                  (NML (NN:[1045..1048] RNA) (HYPH:[1048..1049] -)
                       (NN:[1049..1052] RNA))
                  (NNS:[1053..1060] hybrids))))
            (PP-LOC (IN:[1061..1063] in)
              (NP (JJ:[1064..1071] adrenal) (NNS:[1072..1077] cells)))
            (ADVP (FW:[1078..1080] in) (FW:[1082..1086] vivo))))))
    (.:[1086..1087] .)))

;sentence 9 Span:1088..1259
;To understand why these mRNAs fail to hybridize in vivo, we studied the 
;actions of nuclear proteins on the binding and annealing of their
;complementary  regions in vitro.
;[1112..1117]:substance:"mRNAs"
;[1180..1188]:substance:"proteins"
(SENT
  (S
    (S-PRP
      (NP-SBJ (-NONE-:[1088..1088] *))
      (VP (TO:[1088..1090] To)
        (VP (VB:[1091..1101] understand)
          (SBAR
            (WHADVP-1 (WRB:[1102..1105] why))
            (S
              (NP-SBJ-2 (DT:[1106..1111] these) (NNS:[1112..1117] mRNAs))
              (VP (VBP:[1118..1122] fail)
                (S
                  (NP-SBJ-2 (-NONE-:[1122..1122] *))
                  (VP (TO:[1123..1125] to)
                    (VP (VB:[1126..1135] hybridize)
                      (ADVP (FW:[1136..1138] in) (FW:[1139..1143] vivo)))))
                (ADVP-PRP-1 (-NONE-:[1143..1143] *T*))))))))
    (,:[1143..1144] ,)
    (NP-SBJ (PRP:[1145..1147] we))
    (VP (VBD:[1148..1155] studied)
      (NP
        (NP (DT:[1156..1159] the) (NNS:[1161..1168] actions))
        (PP (IN:[1169..1171] of)
          (NP (JJ:[1172..1179] nuclear) (NNS:[1180..1188] proteins)))
        (PP (IN:[1189..1191] on)
          (NP
            (NP (DT:[1192..1195] the) (NN:[1196..1203] binding)
                (CC:[1204..1207] and) (NN:[1208..1217] annealing))
            (PP (IN:[1218..1220] of)
              (NP (PRP$:[1221..1226] their) (JJ:[1227..1240] complementary)
                  (NNS:[1242..1249] regions))))))
      (ADVP (FW:[1250..1252] in) (FW:[1253..1258] vitro)))
    (.:[1258..1259] .)))

;sentence 10 Span:1260..1387
;The nucleation of interstrand annealing was kinetically  favored over binding
;and was efficiently promoted by nuclear extracts.
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1260..1263] The) (NN:[1264..1274] nucleation))
      (PP (IN:[1275..1277] of)
        (NP (JJ:[1278..1289] interstrand) (NN:[1290..1299] annealing))))
    (VP
      (VP (VBD:[1300..1303] was)
        (ADVP (RB:[1304..1315] kinetically))
        (VP (VBN:[1317..1324] favored)
          (NP-1 (-NONE-:[1324..1324] *))
          (PP (IN:[1325..1329] over)
            (NP (NN:[1330..1337] binding)))))
      (CC:[1338..1341] and)
      (VP (VBD:[1342..1345] was)
        (ADVP (RB:[1346..1357] efficiently))
        (VP (VBN:[1358..1366] promoted)
          (NP-1 (-NONE-:[1366..1366] *))
          (PP (IN:[1367..1369] by)
            (NP (JJ:[1370..1377] nuclear) (NNS:[1378..1386] extracts))))))
    (.:[1386..1387] .)))

;sentence 11 Span:1388..1797
;However,  RNA-RNA strand zippering was inhibited, suggesting that protein
;binding and/or  stable RNA secondary structures contribute to discontiguous
;base pairing.  Increasing concentrations of nuclear proteins increased the
;relative proportion  of these RNAs in perfect RNase-resistant duplexes but
;reached only about 20% of  the total available RNA strands at saturating
;concentrations of nuclear  proteins.
;[1398..1401]:substance:"RNA"
;[1402..1405]:substance:"RNA"
;[1454..1461]:substance:"protein"
;[1485..1488]:substance:"RNA"
;[1590..1598]:substance:"proteins"
;[1643..1647]:substance:"RNAs"
;[1659..1683]:substance:"RNase-resistant duplexes"
;[1707..1710]:quantitative-value:"20%"
;[1735..1738]:substance:"RNA"
;[1788..1796]:substance:"proteins"
(SENT
  (S
    (ADVP (RB:[1388..1395] However))
    (,:[1395..1396] ,)
    (NP-SBJ-1
      (NML (NN:[1398..1401] RNA) (HYPH:[1401..1402] -) (NN:[1402..1405] RNA))
      (NN:[1406..1412] strand) (NN:[1413..1422] zippering))
    (VP (VBD:[1423..1426] was)
      (VP (VBN:[1427..1436] inhibited)
        (NP-1 (-NONE-:[1436..1436] *))
        (,:[1436..1437] ,)
        (S-ADV
          (NP-SBJ (-NONE-:[1437..1437] *))
          (VP (VBG:[1438..1448] suggesting)
            (SBAR (IN:[1449..1453] that)
              (S
                (NP-SBJ
                  (NP (NN:[1454..1461] protein) (NN:[1462..1469] binding))
                  (CC:[1470..1476] and/or)
                  (NP (JJ:[1478..1484] stable) (NN:[1485..1488] RNA)
                      (JJ:[1489..1498] secondary) (NNS:[1499..1509] structures)))
                (VP (VBP:[1510..1520] contribute)
                  (PP-CLR (TO:[1521..1523] to)
                    (NP (JJ:[1524..1537] discontiguous) (NN:[1538..1542] base)
                        (NN:[1543..1550] pairing))))))))))
    ('':[1550..1551] .))
  (S
    (NP-SBJ
      (NP (VBG:[1553..1563] Increasing) (NNS:[1564..1578] concentrations))
      (PP (IN:[1579..1581] of)
        (NP (JJ:[1582..1589] nuclear) (NNS:[1590..1598] proteins))))
    (VP
      (VP (VBD:[1599..1608] increased)
        (NP
          (NP (DT:[1609..1612] the) (JJ:[1613..1621] relative)
              (NN:[1622..1632] proportion))
          (PP (IN:[1634..1636] of)
            (NP (DT:[1637..1642] these) (NNS:[1643..1647] RNAs))))
        (PP (IN:[1648..1650] in)
          (NP (JJ:[1651..1658] perfect)
            
            (ADJP (NN:[1659..1664] RNase) (HYPH:[1664..1665] -)
                  (JJ:[1665..1674] resistant))
            (NNS:[1675..1683] duplexes))))
      (CC:[1684..1687] but)
      (VP (VBD:[1688..1695] reached)
        (NP
          (NP (RB:[1696..1700] only)
            (QP (IN:[1701..1706] about) (CD:[1707..1709] 20))
            (NN:[1709..1710] %))
          (PP (IN:[1711..1713] of)
            (NP (DT:[1715..1718] the) (JJ:[1719..1724] total)
                (JJ:[1725..1734] available) (NN:[1735..1738] RNA)
                (NNS:[1739..1746] strands))))
        (PP (IN:[1747..1749] at)
          (NP
            (NP (VBG:[1750..1760] saturating) (NNS:[1761..1775] concentrations))
            (PP (IN:[1776..1778] of)
              (NP (JJ:[1779..1786] nuclear) (NNS:[1788..1796] proteins)))))))
    (.:[1796..1797] .)))
;ERROR_Sentence has multiple Children (Sentence Error)[1388..1797]::S:S:

;sentence 12 Span:1798..1993
;Preincubation of either of the two single-stranded RNAs with nuclear 
;proteins strongly inhibited the nucleation step of annealing, whereas 
;preincubation of both strands abolished the annealing.
;[1849..1853]:substance:"RNAs"
;[1868..1876]:substance:"proteins"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1798..1811] Preincubation))
      (PP (IN:[1812..1814] of)
        (NP
          (NP (DT:[1815..1821] either))
          (PP (IN:[1822..1824] of)
            (NP (DT:[1825..1828] the) (CD:[1829..1832] two)
              (ADJP (JJ:[1833..1839] single) (HYPH:[1839..1840] -)
                    (JJ:[1840..1848] stranded))
              (NNS:[1849..1853] RNAs)))))
      (PP (IN:[1854..1858] with)
        (NP (JJ:[1859..1866] nuclear) (NNS:[1868..1876] proteins))))
    (ADVP (RB:[1877..1885] strongly))
    (VP (VBD:[1886..1895] inhibited)
      (NP
        (NP (DT:[1896..1899] the) (NN:[1900..1910] nucleation)
            (NN:[1911..1915] step))
        (PP (IN:[1916..1918] of)
          (NP (NN:[1919..1928] annealing))))
      (,:[1928..1929] ,)
      (SBAR-ADV (IN:[1930..1937] whereas)
        (S
          (NP-SBJ
            (NP (NN:[1939..1952] preincubation))
            (PP (IN:[1953..1955] of)
              (NP (DT:[1956..1960] both) (NNS:[1961..1968] strands))))
          (VP (VBD:[1969..1978] abolished)
            (NP (DT:[1979..1982] the) (NN:[1983..1992] annealing))))))
    (.:[1992..1993] .)))

;sentence 13 Span:1994..2179
;RNase footprinting of the  wild type and mutagenized overlapping transcripts
;suggested that  sequence-specific binding of nuclear proteins is limited to
;the 5'-half of each  RNA strand.
;[1994..1999]:substance:"RNase"
;[2059..2070]:substance:"transcripts"
;[2124..2132]:substance:"proteins"
;[2168..2171]:substance:"RNA"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1994..1999] RNase) (NN:[2000..2012] footprinting))
      (PP (IN:[2013..2015] of)
        (NP (DT:[2016..2019] the)
          (NML
            (NML (JJ:[2021..2025] wild) (NN:[2026..2030] type)
              (NML-2 (-NONE-:[2030..2030] *P*)))
            (CC:[2031..2034] and)
            (NML (VBN:[2035..2046] mutagenized) (VBG:[2047..2058] overlapping)
              (NML-2 (NNS:[2059..2070] transcripts)))))))
    (VP (VBD:[2071..2080] suggested)
      (SBAR (IN:[2081..2085] that)
        (S
          (NP-SBJ-1
            (NP
              (ADJP (NN:[2087..2095] sequence) (HYPH:[2095..2096] -)
                    (JJ:[2096..2104] specific))
              (NN:[2105..2112] binding))
            (PP (IN:[2113..2115] of)
              (NP (JJ:[2116..2123] nuclear) (NNS:[2124..2132] proteins))))
          (VP (VBZ:[2133..2135] is)
            (VP (JJ:[2136..2143] limited)
              (NP-1 (-NONE-:[2143..2143] *))
              (PP-CLR (TO:[2144..2146] to)
                (NP
                  (NP (DT:[2147..2150] the)
                    (NML (CD:[2151..2152] 5) (SYM:[2152..2153] '))
                    (HYPH:[2153..2154] -) (NN:[2154..2158] half))
                  (PP (IN:[2159..2161] of)
                    (NP (DT:[2162..2166] each) (NN:[2168..2171] RNA)
                        (NN:[2172..2178] strand))))))))))
    (.:[2178..2179] .)))

;section 14 Span:2180..2462
;These results indicate that the transcription of complementary, 
;opposite-strand RNAs is not a mechanism for the regulation of the abundance
;of  adrenal P450c21 mRNA and suggest that nuclear proteins strongly interfere
;with  interstrand RNA base pairing in vitro as well as in vivo.
;[2261..2265]:substance:"RNAs"
;[2333..2345]:substance:"P450c21 mRNA"
;[2371..2379]:substance:"proteins"
;[2417..2420]:substance:"RNA"
(SEC
  (S
    (NP-SBJ (DT:[2180..2185] These) (NNS:[2186..2193] results))
    (VP
      (VP (VBP:[2194..2202] indicate)
        (SBAR (IN:[2203..2207] that)
          (S
            (NP-SBJ
              (NP (DT:[2208..2211] the) (NN:[2212..2225] transcription))
              (PP (IN:[2226..2228] of)
                (NP (JJ:[2229..2242] complementary) (,:[2242..2243] ,)
                  (NML (JJ:[2245..2253] opposite) (HYPH:[2253..2254] -)
                       (NN:[2254..2260] strand))
                  (NNS:[2261..2265] RNAs))))
            (VP (VBZ:[2266..2268] is) (RB:[2269..2272] not)
              (NP-PRD
                (NP (DT:[2273..2274] a) (NN:[2275..2284] mechanism))
                (PP (IN:[2285..2288] for)
                  (NP
                    (NP (DT:[2289..2292] the) (NN:[2293..2303] regulation))
                    (PP (IN:[2304..2306] of)
                      (NP
                        (NP (DT:[2307..2310] the) (NN:[2311..2320] abundance))
                        (PP (IN:[2321..2323] of)
                          (NP (JJ:[2325..2332] adrenal)
                             (NN:[2333..2340] P450c21) (NN:[2341..2345] mRNA))))))))))))
      (CC:[2346..2349] and)
      (VP (VBP:[2350..2357] suggest)
        (SBAR (IN:[2358..2362] that)
          (S
            (NP-SBJ (JJ:[2363..2370] nuclear) (NNS:[2371..2379] proteins))
            (ADVP (RB:[2380..2388] strongly))
            (VP (VB:[2389..2398] interfere)
              (PP-CLR (IN:[2399..2403] with)
                (NP (JJ:[2405..2416] interstrand) (NN:[2417..2420] RNA)
                    (NN:[2421..2425] base) (NN:[2426..2433] pairing)))
              (ADVP
                (ADVP (FW:[2434..2436] in) (FW:[2437..2442] vitro))
                (CONJP (RB:[2443..2445] as) (RB:[2446..2450] well)
                       (IN:[2451..2453] as))
                (ADVP (FW:[2454..2456] in) (FW:[2457..2461] vivo))))))))
    (.:[2461..2462] .)))
;ERROR_Entity in section[2261..2265]:substance "RNAs"
;ERROR_Entity in section[2333..2345]:substance "P450c21 mRNA"
;ERROR_Entity in section[2371..2379]:substance "proteins"
;ERROR_Entity in section[2417..2420]:substance "RNA"

;section 15 Span:2466..2510
;PMID: 8614402 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2466..2470] PMID) (::[2470..2471] :) (CD:[2472..2479] 8614402)
        (IN:[2480..2481] -LSB-) (NNP:[2481..2487] PubMed) (HYPH:[2488..2489] -)
        (JJ:[2490..2497] indexed) (IN:[2498..2501] for)
        (NNP:[2502..2510] MEDLINE-RSB-)))
